Wellness Franchise Opportunities

Product LaunchMay, 05 2015

Pharma giant Mylan launches hepatitis-C Sovaldi tablets in India

Mylan Pharmaceuticals, the subsidiary of Pharma giant Mylan NV has launched Gilead Sciences' Sovaldi or sofosbuvir 400 mg tablets to treat chronic hepatitis-C infection.

By Agencies

Pharma giant Mylan NV has announced that its subsidiary Mylan Pharmaceuticals has launched Gilead Sciences' Sovaldi (sofosbuvir 400 mg tablets) in India.

Sovaldi is used for the treatment of chronic hepatitis-C infection as a component of a combination anti-viral treatment.

About 12 million people are chronically infected with hepatitis-C in India, as per a rough estimate, said Mylan in a release.

In February this year, Gilead appointed Mylan as its exclusive distributor of Sovaldi in India.

Significantly, Rajiv Malik, President, Mylan said that the company have a history of partnering with Gilead to tackle key public health issues in India and across the globe, beginning with expanding access to high quality and affordable HIV/AIDS anti-retrovirals.

"We are proud to continue our work together with the launch of Sovaldi as it supports our joint commitment to meeting the unmet medical needs of patients in India," noted Malik.

Gregg Alton, Executive Vice-President, Corporate and Medical Affairs, Gilead Sciences said it makes an important milestone in the company's ongoing effort to make its hepatitis-C medicines accessible to as many patients, in as many places, as quickly as possible.

Reportedly, Sovaldi is sold by Mylan's dedicated sales force as part of its Hepato Care segment.

Related: How new player SamiDirect’s Johara Anti Cellulite cream may lift market competition

Click Here to add Comment
Please add your Comment
Sell Franchise 2017

Newsletter Signup

Submit your email address to receive the latest updates on news & host of opportunities from Wellness India.


Magazines & Books

Read the latest franchising magazines and books to get comprehensive and up-to-date information on leading franchise systems, trends and more.

Recommended For You

Newsletter Signup
Submit your email address to receive the latest updates on news & host of opportunities.
Well Ness India

Copyright © 2009 - 2017 Franchise India Holdings Ltd.

The information contained herein is of generic nature only, and Franchise India is not, by means of this website or any part thereof, rendering professional advice or services. Before making any decision or taking any action that might affect your finances or business, you should consult a qualified professional advisor. Your use of this website or any of its pages or links given, is at your own risk and you assume full responsibility and risk of loss resulting from your usage. With respect to use of the website, kindly visit www.franchiseindia.com/terms.